Cognition Therapeutics Inc (CGTX) stock
CGTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.63−0.01 (-1.39%)
Close on Nov 17, 2026Market cap $59.90MP/E –Yield –
Cognition Therapeutics cash
Cash and short-term investments held at the end of each period.
Cognition Therapeutics's cash was $34.01M at Jun 30, 2026. For fiscal 2025 it was $36.81M, up 47.2% from the year before. The highest annual figure on record is $54.72M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $36.81M | +47.2% |
| FY2024 | Dec 31, 2024 | $25.01M | -16.4% |
| FY2023 | Dec 31, 2023 | $29.92M | -28.0% |
| FY2022 | Dec 31, 2022 | $41.56M | -24.0% |
| FY2021 | Dec 31, 2021 | $54.72M | +954.6% |
| FY2020 | Dec 31, 2020 | $5.19M | +79.6% |
| FY2019 | Dec 31, 2019 | $2.89M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $34.01M | +216.6% |
| Q1 FY2026 | Mar 31, 2026 | $31.13M | +89.5% |
| Q4 FY2025 | Dec 31, 2025 | $36.81M | +47.2% |
| Q3 FY2025 | Sep 30, 2025 | $39.33M | +78.7% |
| Q2 FY2025 | Jun 30, 2025 | $10.74M | -62.3% |
| Q1 FY2025 | Mar 31, 2025 | $16.43M | -52.6% |
| Q4 FY2024 | Dec 31, 2024 | $25.01M | -16.4% |
| Q3 FY2024 | Sep 30, 2024 | $22.01M | -33.2% |
| Q2 FY2024 | Jun 30, 2024 | $28.53M | -23.3% |
| Q1 FY2024 | Mar 31, 2024 | $34.67M | -10.7% |
| Q4 FY2023 | Dec 31, 2023 | $29.92M | -28.0% |
| Q3 FY2023 | Sep 30, 2023 | $32.97M | -29.3% |
| Q2 FY2023 | Jun 30, 2023 | $37.19M | -18.7% |
| Q1 FY2023 | Mar 31, 2023 | $38.81M | -24.7% |
| Q4 FY2022 | Dec 31, 2022 | $41.56M | -24.0% |
| Q3 FY2022 | Sep 30, 2022 | $46.61M | +460.9% |
| Q2 FY2022 | Jun 30, 2022 | $45.77M | +305.1% |
| Q1 FY2022 | Mar 31, 2022 | $51.51M | +285.2% |
| Q4 FY2021 | Dec 31, 2021 | $54.72M | +954.6% |
| Q3 FY2021 | Sep 30, 2021 | $8.31M | +58.5% |
| Q2 FY2021 | Jun 30, 2021 | $11.30M | +291.0% |
| Q1 FY2021 | Mar 31, 2021 | $13.37M | – |
| Q4 FY2020 | Dec 31, 2020 | $5.19M | – |
| Q3 FY2020 | Sep 30, 2020 | $5.24M | – |
| Q4 FY2019 | Dec 31, 2019 | $2.89M | – |
See a number that looks wrong?